RBC Sees Lower Guidance at Valeant (VRX); PT Trimmed to $35
- Donald Trump Sworn in as 45th U.S. President
- Wall Street ends higher as Trump becomes president
- Walgreens Boots Alliance (WBA) Said to Face Antitrust Concern for Rite Aid (RAD) Fix - Bloomberg
- Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
- Apple (AAPL) Sues Qualcomm (QCOM) Over Patent Royalties in Antitrust Case - Bloomberg
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
RBC Capital analyst Douglas Miehm reiterated his Sector Perform rating on Valeant Pharmaceuticals (NYSE: VRX) while trimming his price target to $35.00 (from $36.00), saying guidance may be lowered.
"Following a reiteration of guidance in August, we believe management may lower guidance due to increased operating expenses associated with recovery of the business," Miehm commented. "While we believe the Street is expecting lowered guidance, recent share price weakness has likely largely discounted this likelihood. We have revised our forecasts to reflect timing of the derm recovery and higher incremental operating expenses."
They anticipate that Valeant will lower its 2016 guidance to ~$9.7–9.9B in revenue (from $9.9–10.1B), $4.5–4.7B in Adj. EBITDA (from $4.8–4.95B), and $6.25–6.55 in Adj. EPS (from $6.60–7.00). The firm's revised 2016 forecasts include $9.84B in revenue, $4.61B in Adj. EBITDA, and $6.26 in Adj. EPS.
Shares of Valeant Pharmaceuticals closed at $22.94 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Deutsche Bank Sees 'Encouraging' Short-Term Set-Up in Valeant (VRX)
- Union Pacific (UNP) PT Raised to $120 at Aegis Capital Following Solid 4Q
- UPDATE: SunTrust Robinson Humphrey Downgrades Simon Property Group (SPG) to Hold
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change
Related EntitiesRBC Capital
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!